Best in Biotech 28 Dec 2020 A Year to Remember: The Biggest European Biotech News in 2020 The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. After the many drug approvals, startup foundations, and venture capital highs we saw in 2019, it looked like 2020 was going to be a comfortable […] December 28, 2020 - 12 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 May 2020 Genfit’s Phase III Drug Fails to Treat NASH, But New Players On Horizon Patients with the chronic liver disease NASH must now wait even longer for an approved treatment, after French biotech Genfit’s phase III trial of its lead drug candidate elafibranor failed. But, newer players, such as Novo Nordisk, are edging closer to the market. This year, it is predicted that NASH — the full name of […] May 13, 2020 - 4 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 30 Jul 2019 The First Approved NASH Therapy? Genfit is poised to become the first company to get a treatment for NASH to market — something that could happen as early as 2020, should its late 2019 phase III trial results be positive. I spoke to Dean Hum, the current COO and CSO of Genfit, to find out more about the company’s 20-year […] July 30, 2019 - 6 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jun 2019 Genfit’s NASH Drug to Be Developed in China in Deal Worth up to €200M The US-Chinese company Terns Pharmaceuticals will develop and commercialize Genfit’s phase III drug elafibranor for the chronic liver disease NASH in China. As part of the deal, Genfit will receive a €31M ($35M) upfront fee and up to €170M ($193M) in developmental milestone payments. The two companies will also collaborate on other development programs for […] June 25, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Mar 2019 Genfit Gets Ready to Launch Drug for Untreated Liver Disease Raising €120M After some big failures from its top competitors earlier this year, French company Genfit has done an IPO to prepare the launch of its drug for NASH, a chronic liver disease for which there is currently no treatment. Today, Genfit has started trading on Nasdaq. Together with issuing new shares in its existing Euronext Paris […] March 27, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jan 2018 NASH Leader goes Pediatric with Clinical Trial Launch in US The FDA has cleared Genfit to kick off clinical trials to see if its NASH drug, elafibranor, can also help children. Genfit develops diagnostic and therapeutic tools for metabolic and inflammatory diseases, particularly those affecting the liver. Its lead candidate, elafibranor, targets Non-Alcoholic Stato-Hepatitis (NASH), and the company’s plan to begin testing it in children has been supported […] January 23, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Dec 2017 Bored Between the Holidays? Watch these Biotech Videos! Christmas might have passed, but we have more videos for you to watch on a dreary winter day! Here are our highlights from 2017. It’s vacation time! If you’ve worn out the holiday movies, catch up on our biotech ones. It was a busy year, and we produced a lot, thanks to our new Hangouts […] December 28, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2017 Genfit Gets €180M Cash Injection to Bring its Pipeline to Market Elafibranor, Genfit’s lead candidate, will continue its march towards the market with the added boost of massive financial support. Genfit is a leader in the development of diagnostic tools and therapeutics for metabolic and inflammatory diseases. Its lead candidate, elafibranor, targets Non-Alcoholic Stato-Hepatitis (NASH) – an inflammatory disease of the liver. The company has raised €180M by selling bonds […] October 17, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 26 Sep 2017 These Three Fields Are Proving Biotech is The Innovation Powerhouse in Healthcare Biotech is the best source of innovation in R&D, making its companies the darlings of pharma. Which therapeutic fields belong to biotech? “Biotech is typically first in highly innovative fields,” Matt Kapusta, CEO of uniQure told us. Before he became CEO, uniQure brought the world’s first gene therapy to market — completely on its own. Biotech […] September 26, 2017 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 11 Jul 2017 The Advantage for the First Mover in NASH is Limited, says Genfit After we reviewed NASH earlier this year, Genfit’s CSO, Dean Hum, came to speak at Refresh about his company’s strategy in the space. As CSO of Genfit, Dean Hum coordinates the company’s R&D efforts to be first to market in NASH, which represent an untapped market of €37B. The company is counting on its lead […] July 11, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2017 Genfit Delays Phase III Enrollment in the Race for the First NASH Therapy Genfit has announced that closing of enrollment will be delayed up to 6 months. Will this affect its chances to be the first to launch a treatment for NASH? The French biotech Genfit is leading the race to launch the first treatment ever for non-alcoholic steatohepatitis (NASH), a liver disease that affects 30 million people worldwide and has […] April 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Apr 2017 Two Big Pharma Players Team up to Take Over the NASH Space Allergan has entered a clinical collaboration with Novartis to run a Phase IIb study combining its immunomodulator and Novartis’ FXR agonist for NASH. After Allergan snapped up Tobira’s cenicriviroc (CVC) last year in a €1.4B deal, the company is now taking the next step to advance its pipeline in the Non-Alcoholic SteatoHepatitis (NASH) race. The pharma company is going […] April 18, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email